Construction of an Excellent 7 mRNAsi-Related Gene Model Based on Cancer Stem Cells for Predicting Survival Outcome of Cervical Cancer

Figure 11

Explorations of clinical applications for RiskScore. (a) T-cell-inflamed GEP score. (b) Th1/IFNγ gene signature ssGSEA score. (c) Cytolytic activity. (d) Immune checkpoint gene expression level. (e) Difference in TIDE score. (f) RiskScore versus T-cell-inflamed GEP score, Th1/IFNγ gene signature SsGSEA score and Cytolytic activity, immune checkpoint gene expression level, and TIDE score correlation heat map. (g) RiskScore differences between immunotherapy responses in the IMvigor210 cohort. (h) Immunotherapy response distribution between the RiskScore groups in the IMvigor210 cohort. (i) IMvigor210 prognostic differences between the RiskScore groups in the cohort. (j, k) Early-stage groups (stage I+II and stage III+IV), the box plots of the estimated for Paclitaxel, Gemcitabine, and Cisplatin and the relationship between Gefitinib, Mitomycin C, and Sunitinib in TCGA-CESC. (l, m) RiskScore and drug sensitivity.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)